The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Randomised Controlled Trial To Determine Efficacy And Safety Of Prescribed Water Intake To Prevent The Progression Of Autosomal Dominant Polycystic Kidney Disease (PREVENT-ADPKD)
Funder
National Health and Medical Research Council
Funding Amount
$746,751.00
Summary
Increasing the daily intake of water is well known to reduce the risk of developing kidney stones but there is growing evidence that it may also benefit other kidney diseases, particularly autosomal dominant polycystic kidney disease (ADPKD). This study will determine if adequate hydration can slow the progression of ADPKD, and could provide a relatively simple and cheap treatment for preventing the onset of kidney failure due to this disease.
Chronic Kidney Disease: Natural History Of Disease, Cost And Quality Of Life
Funder
National Health and Medical Research Council
Funding Amount
$72,281.00
Summary
Chronic kidney disease (CKD) is present in 12% of Australians aged over 25. CKD is associated with poor health outcomes including cardiovascular disease and progression to End Stage Kidney Disease. Many questions about CKD remain. My research aims to increase our understanding of the natural history of CKD in the Australian population, with focus on outcomes of CKD progression, cardiovascular and all-cause mortality, quality of life, and costs to society.
Periodontal Disease And Chronic Kidney Disease Among Aboriginal Adults; An RCT
Funder
National Health and Medical Research Council
Funding Amount
$1,035,550.00
Summary
Chronic Kidney Disease is a growing public health concern in Australia, especially among Aboriginal populations. It is associated with progression to end stage kidney disease requiring dialysis, cardiovascular disease burden and high mortality. This study will use a randomised controlled trial design to determine if comprehensive periodontal therapy reduces progression of kidney disease among Aboriginal adults with chronic kidney disease residing in Central Australia.
CKD-FIX: A Randomised, Controlled Trial Of Allopurinol In The Slowing Of Kidney Disease Progression
Funder
National Health and Medical Research Council
Funding Amount
$1,917,147.00
Summary
Chronic kidney disease (CKD) is a major public health problem affecting over 1.5 million Australians and is associated with increased risk of death, heart disease and progression to end-stage kidney disease (ESKD). Current treatments to slow progression to ESKD are limited. The CKD-FIX trial aims to find out whether treatment with allopurinol, a commonly used drug for gout prevention, safely and effectively slows CKD progression. This could lead to significant health and economic benefits.
Brm And Brg-1 Protect From Ultraviolet Radiation-induced Skin And Ocular Damage
Funder
National Health and Medical Research Council
Funding Amount
$555,325.00
Summary
Ultraviolet radiation within sunlight is the most important environmental hazard to which Australians are exposed. It causes cancers of the skin and eye, in addition to other forms of skin and eye damage. However sunlight also has health benefits such as vitamin D production. To protect our health from the sun we need to understand how it causes damage and the meachanisms involved. We have discovered a new pathway that we plan to study, called Brm and Brg-1, that provides protection from UV.
How Do Bone-active Drugs Increase Patient Survival?
Funder
National Health and Medical Research Council
Funding Amount
$613,952.00
Summary
Bisphosphonates are a class of drugs used to prevent bone destruction in diseases such as osteoporosis. Evidence is emerging that these drugs also act on cells outside the skeleton to have additional beneficial effects, for example prolonging patient survival. This project will identify the cells affected and the mechanisms involved. With this knowledge, these drugs could be used more effectively and in different ways for the prevention or treatment of cancer and chronic human illnesses.
Centre Of Research Excellence: Partnering With Patients With Chronic Kidney Disease To Transform Care And Outcomes (CRE-PACT)
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
CRE-PACT will partner with patients to generate and translate new high-priority evidence to improve outcomes that are important to people living with chronic kidney disease (CKD). We will address the topics and questions most important to patients. We will build the next generation of research leaders and a community of research-ready patient-partners. There will be an integrated pathway for evidence translation and implementation at a global scale to improve patient-centred outcomes.
Myeloma Plasma Cell Dormancy - 'Eradicating The Sleeping Giant'
Funder
National Health and Medical Research Council
Funding Amount
$834,428.00
Summary
Multiple myeloma is a fatal cancer that develops in the skeleton. Current therapies are initially effective, but patients develop resistance and the disease returns. This makes the search for drugs to overcome resistance a priority. Myeloma cells can hide in bone in a dormant state where they are insensitive to chemotherapy. We have identified new drug targets in dormant cells. We are investigating whether these new targets can be used eradicate myeloma cells and cure the disease.
Role Of IGF Binding Protein-3 (IGFBP-3) And IGFBP-5 As Modulators Of Nuclear Hormone Signalling
Funder
National Health and Medical Research Council
Funding Amount
$465,750.00
Summary
The insulin-like growth factors are small proteins involved in the growth of most tissues. Their actions are regulated by binding to larger proteins (known as IGFBPs) in the bloodstream and outside the cell. However, some IGFBPs are also found inside cells, where they seem to carry out other functions. We believe that two of these binding proteins, IGFBP-3 and IGFBP-5, change the way cells respond to vitamin A and vitamin D. These two vitamins are important in cell growth and in the way certain ....The insulin-like growth factors are small proteins involved in the growth of most tissues. Their actions are regulated by binding to larger proteins (known as IGFBPs) in the bloodstream and outside the cell. However, some IGFBPs are also found inside cells, where they seem to carry out other functions. We believe that two of these binding proteins, IGFBP-3 and IGFBP-5, change the way cells respond to vitamin A and vitamin D. These two vitamins are important in cell growth and in the way certain cells perform specialised functions. In test-tube experiments, IGFBP-3 and IGFBP-5 interact directly with the receptors that regulate the effects of these hormones. If the same thing happens inside the cell, IGFBP-3 and IGFBP-5 could change the way these receptors respond to signals from outside the cell. We will investigate what effect these IGFBPs have in living cells and in whole animals and how this may relate to human disease. If we are able to understand how IGFBP-3 and IGFBP-5 affect the way cells respond to vitamin A and D, then we may be able to develop new ways to treat certain human diseases.Read moreRead less
Epimutations As Germ-line Defects In Hereditary Cancer Syndromes
Funder
National Health and Medical Research Council
Funding Amount
$385,925.00
Summary
Traditionally familial cancers were thought to be caused and inherited by spelling mistakes within the genetic code of cancer prevention genes. Our group has found that a 'chemical coat' around the MLH1 gene, causing it to be switched off, can also be inherited in some cases of bowel cancer, without any mistakes within the gene's code. We will determine if this 'coat' causes other types of cancer and if this runs in families. We also hope to find out how the coat is formed and may be reversed.